Literature DB >> 31611366

Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease.

Seong Mi Moon1, In Young Yoo2, Hee Jae Huh2, Nam Yong Lee2, Byung Woo Jhun3.   

Abstract

We evaluated the efficacy of intermittent azithromycin and ethambutol therapy for noncavitary Mycobacterium avium complex pulmonary disease (MAC-PD). Twenty-nine (76%) of 38 patients achieved sputum culture conversion after 12 months of treatment, and sputum smear positivity was an independent factor for failure to achieve culture conversion (adjusted odds ratio, 26.7; 95% confidence interval, 2.1 to 339.9; P = 0.011). Intermittent azithromycin and ethambutol may be an optional treatment regimen for noncavitary MAC-PD.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium avium complex; ethambutol; intermittent therapy; macrolide

Year:  2019        PMID： 31611366      PMCID： PMC7187621          DOI： 10.1128/AAC.01787-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.

Authors:  Byeong-Ho Jeong; Kyeongman Jeon; Hye Yun Park; Su-Young Kim; Kyung Soo Lee; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Am J Respir Crit Care Med       Date:  2015-01-01       Impact factor: 21.405

Review 2.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

3.  Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype.

Authors:  Won-Jung Koh; Seong Mi Moon; Su-Young Kim; Min-Ah Woo; Seonwoo Kim; Byung Woo Jhun; Hye Yun Park; Kyeongman Jeon; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Myung Jin Chung; Kyung Soo Lee; Sung Jae Shin; Charles L Daley; Hojoong Kim; O Jung Kwon
Journal:  Eur Respir J       Date:  2017-09-27       Impact factor: 16.671

4.  The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.

Authors:  Jakko van Ingen; Eric F Egelund; Adrah Levin; Sarah E Totten; Martin J Boeree; Johan W Mouton; Rob E Aarnoutse; Leonid B Heifets; Charles A Peloquin; Charles L Daley
Journal:  Am J Respir Crit Care Med       Date:  2012-06-28       Impact factor: 21.405

Review 5.  British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).

Authors:  Charles S Haworth; John Banks; Toby Capstick; Andrew J Fisher; Thomas Gorsuch; Ian F Laurenson; Andrew Leitch; Michael R Loebinger; Heather J Milburn; Mark Nightingale; Peter Ormerod; Delane Shingadia; David Smith; Nuala Whitehead; Robert Wilson; R Andres Floto
Journal:  Thorax       Date:  2017-11       Impact factor: 9.139

6.  Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease.

Authors:  Won-Jung Koh; Byeong-Ho Jeong; Kyeongman Jeon; Soo-Youn Lee; Sung Jae Shin
Journal:  Am J Respir Crit Care Med       Date:  2012-08-09       Impact factor: 21.405

7.  Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection.

Authors:  R J Wallace; B A Brown; D E Griffith; W Girard; K Tanaka
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

Review 8.  Epidemiology of Nontuberculous Mycobacteriosis.

Authors:  Jennifer Adjemian; Shelby Daniel-Wayman; Emily Ricotta; D Rebecca Prevots
Journal:  Semin Respir Crit Care Med       Date:  2018-08-02       Impact factor: 3.119

9.  Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study.

Authors:  Seiichi Miwa; Masahiro Shirai; Mikio Toyoshima; Toshihiro Shirai; Kazumasa Yasuda; Koshi Yokomura; Takashi Yamada; Masafumi Masuda; Naoki Inui; Kingo Chida; Takafumi Suda; Hiroshi Hayakawa
Journal:  Ann Am Thorac Soc       Date:  2014-01

10.  Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes.

Authors:  Hitoshi Shimomura; Sena Andachi; Takahiro Aono; Akira Kigure; Yosuke Yamamoto; Atsushi Miyajima; Takashi Hirota; Keiko Imanaka; Toru Majima; Hidenori Masuyama; Koichiro Tatsumi; Takao Aoyama
Journal:  J Pharm Health Care Sci       Date:  2015-11-14
View more
  4 in total

1.  Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease.

Authors:  Ganghee Chae; Yea Eun Park; Yong Pil Chong; Hyun Joo Lee; Tae Sun Shim; Kyung-Wook Jo
Journal:  Antimicrob Agents Chemother       Date:  2022-08-11       Impact factor: 5.938

2.  Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.

Authors:  Jang Ho Lee; Yea Eun Park; Yong Pil Chong; Tae Sun Shim; Kyung-Wook Jo
Journal:  Antimicrob Agents Chemother       Date:  2021-12-20       Impact factor: 5.938

3.  An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies.

Authors:  Vidhisha V Sonawane; Mike M Ruth; Lian J Pennings; Elin M Svensson; Heiman F L Wertheim; Wouter Hoefsloot; Jakko van Ingen
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

4.  Treatment outcomes of Mycobacterium avium complex pulmonary disease according to disease severity.

Authors:  Bo-Guen Kim; Byung Woo Jhun; Hojoong Kim; O Jung Kwon
Journal:  Sci Rep       Date:  2022-02-04       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.